Anat Achiron
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Anat Achiron has a total of 134 co-authors. Here are the top co-authors by number of shared publications:
- Michael Gurevich
Multiple Sclerosis Center, Sheba Medical Center, Ramat Gan, Israel
13 shared publications - Yoram Barak
Department of Psychological Medicine, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand
13 shared publications M. Gurevich
7 shared publicationsM. Mandel
Blood Bank Center, Sheba Medical Center, Tel-Hashomer, Sackler School of Medicine, Tel-Aviv University, Israel
6 shared publicationsD. Magalashvili
5 shared publicationsShmuel Miron
5 shared publications
Latest Publications
- Open Access
- 29 November 2025
- Published by S. Karger AG in European Neurology
- Vol. 89 (1) , 13-21
Digital Color Vision Testing Reveals Widespread Cone Dysfunction in Multiple Sclerosis Independent of Optic Neuritis
Introduction: We aimed to investigate the prevalence and pattern of color vision deficiency (CVD) in relapsing-remitting multiple sclerosis (RRMS) patients, with or without a history of optic neuritis (ON), and to assess its potential as a marker of subclinical optic pathway dysfunction. Methods: Color vision was assessed in a large cohort of 345 RRMS patients using the Waggoner Computerized Color Vision Test, screening for protan, deutan, tritan, and composite color deficiencies, with severity grading based on score thresholds. Statistical differences between eyes with a history of ON, fellow eyes without ON, and eyes from MS patients with no history of ON were analyzed using multivariable logistic regression, controlled for age, gender, disease duration, Expanded Disability Status Scale, and treatment status. Results: Out of the 676 eyes analyzed, CVD was observed in 76.0% of ON-affected eyes, 65.1% of fellow eyes without ON, and 62.3% of eyes from patients without ON. Multivariable logistic regression showed ON-affected eyes had significantly higher odds of severe CVD compared to fellow eyes (OR = 2.48, p = 0.020), which in turn had higher odds of moderate CVD compared to the no-ON group (OR = 2.27, p = 0.010). Conversely, the no-ON group had higher odds of mild CVD compared to fellow eyes without ON (OR = 2.01, p = 0.003). Composite CVD was the most frequent type (57.7%), with tritan deficiencies being the most common pure type (39.9%). Fellow eyes demonstrated higher odds of composite CVD compared to the no-ON group (OR = 1.97, p = 0.016). Conclusions: CVD is highly prevalent in MS even without clinical ON, indicating diffuse, subclinical optic pathway damage.
- 29 November 2025
- Published by S. Karger AG in European Neurology
- Vol. 89 (1) , 13-21
Open AccessDigital Color Vision Testing Reveals Widespread Cone Dysfunction in Multiple Sclerosis Independent of Optic Neuritis
Introduction: We aimed to investigate the prevalence and pattern of color vision deficiency (CVD) in relapsing-remitting multiple sclerosis (RRMS) patients, with or without a history of optic neuritis (ON), and to assess its potential as a marker of subclinical optic pathway dysfunction. Methods: Color vision was assessed in a large cohort of 345 RRMS patients using the Waggoner Computerized Color Vision Test, screening for protan, deutan, tritan, and composite color deficiencies, with severity grading based on score thresholds. Statistical differences between eyes with a history of ON, fellow eyes without ON, and eyes from MS patients with no history of ON were analyzed using multivariable logistic regression, controlled for age, gender, disease duration, Expanded Disability Status Scale, and treatment status. Results: Out of the 676 eyes analyzed, CVD was observed in 76.0% of ON-affected eyes, 65.1% of fellow eyes without ON, and 62.3% of eyes from patients without ON. Multivariable logistic regression showed ON-affected eyes had significantly higher odds of severe CVD compared to fellow eyes (OR = 2.48, p = 0.020), which in turn had higher odds of moderate CVD compared to the no-ON group (OR = 2.27, p = 0.010). Conversely, the no-ON group had higher odds of mild CVD compared to fellow eyes without ON (OR = 2.01, p = 0.003). Composite CVD was the most frequent type (57.7%), with tritan deficiencies being the most common pure type (39.9%). Fellow eyes demonstrated higher odds of composite CVD compared to the no-ON group (OR = 1.97, p = 0.016). Conclusions: CVD is highly prevalent in MS even without clinical ON, indicating diffuse, subclinical optic pathway damage.
- 28 July 2017
- Published by Springer Nature in NeuroMolecular Medicine
- Vol. 19 (2-3) , 406-412
Experimental Autoimmune Encephalomyelitis Ameliorated by Passive Transfer of Polymerase 1-Silenced MOG35-55 Lymphatic Node Cells: Verification of a Novel Therapeutic Approach in Multiple Sclerosis
In the current study, we present an innovative concept based on the knowledge that enhancing naturally occurring biological mechanisms is effective in preventing neuronal damage and maintaining low disease activity in about 15% of multiple sclerosis (MS) patients presenting the benign type of MS. Recently, we have demonstrated that low disease activity in benign MS is associated with suppression of RNA polymerase 1 (POL1) pathway; therefore, targeting POL1 transcription machinery as a strategy for suppressing active forms of MS is suggested. To further establish our approach, we aimed to suppress POL1 pathway by silencing of the POL1-related RRN3, POLR1D and LRPPRC genes in specific MOG35-55-activated lymphocytes and assess their capacity to induce experimental autoimmune encephalomyelitis (EAE) by passive transfer. We have demonstrated that silencing of specific POL1 pathway-related genes significantly decreased viability and increased the proportion of CD4+/AnnexinV+/PI+ apoptotic cells in MOG35-55-primed lymphocytes. POL1-gene silencing significantly decreased the proportion of CD4+IL17+ and increased proportion of CD4+IL10+ and CD4+TNFa+ lymphocytes that occurred simultaneously with over-presentation of Treg CD4+CD25+FoxP3+ cells. Passive transfer of MOG35-55-primed lymphocytes after POL1-gene silencing suppressed EAE development in mice as demonstrated by delayed onset and peak of disease accompanied by significantly lower maximal and cumulative EAE scores. Our study supports a basis for direct targeting of POL1 transcription pathway as a strategy for selective induction of apoptosis and suppression of inflammation in EAE and consequently paves the way for innovative and targeted MS therapeutic strategy that is based on naturally existing biological mechanism.
- 28 July 2017
- Published by Springer Nature in NeuroMolecular Medicine
- Vol. 19 (2-3) , 406-412
Experimental Autoimmune Encephalomyelitis Ameliorated by Passive Transfer of Polymerase 1-Silenced MOG35-55 Lymphatic Node Cells: Verification of a Novel Therapeutic Approach in Multiple Sclerosis
In the current study, we present an innovative concept based on the knowledge that enhancing naturally occurring biological mechanisms is effective in preventing neuronal damage and maintaining low disease activity in about 15% of multiple sclerosis (MS) patients presenting the benign type of MS. Recently, we have demonstrated that low disease activity in benign MS is associated with suppression of RNA polymerase 1 (POL1) pathway; therefore, targeting POL1 transcription machinery as a strategy for suppressing active forms of MS is suggested. To further establish our approach, we aimed to suppress POL1 pathway by silencing of the POL1-related RRN3, POLR1D and LRPPRC genes in specific MOG35-55-activated lymphocytes and assess their capacity to induce experimental autoimmune encephalomyelitis (EAE) by passive transfer. We have demonstrated that silencing of specific POL1 pathway-related genes significantly decreased viability and increased the proportion of CD4+/AnnexinV+/PI+ apoptotic cells in MOG35-55-primed lymphocytes. POL1-gene silencing significantly decreased the proportion of CD4+IL17+ and increased proportion of CD4+IL10+ and CD4+TNFa+ lymphocytes that occurred simultaneously with over-presentation of Treg CD4+CD25+FoxP3+ cells. Passive transfer of MOG35-55-primed lymphocytes after POL1-gene silencing suppressed EAE development in mice as demonstrated by delayed onset and peak of disease accompanied by significantly lower maximal and cumulative EAE scores. Our study supports a basis for direct targeting of POL1 transcription pathway as a strategy for selective induction of apoptosis and suppression of inflammation in EAE and consequently paves the way for innovative and targeted MS therapeutic strategy that is based on naturally existing biological mechanism.
- 15 January 2015
- Published by Association for Research in Vision and Ophthalmology (ARVO) in Investigative Ophthalmology & Visual Science
- Vol. 56 (2) , 1349-1356
The Role of B Cells in the Early Onset of the First Demyelinating Event of Acute Optic Neuritis
Purpose. We evaluated the molecular pathways that operate in the early phase of acute optic neuritis (ON) by studying gene expression profiles of peripheral blood mononuclear cells (PBMCs) subpopulations, including CD19+ B cells, CD14+ macrophages, and CD4+ and CD8+ T cells. Methods. Samples of PBMC subpopulations were obtained from 18 MS patients within 96 hours of the acute onset of the first demyelinating event of ON, and from 14 age- and sex-matched healthy subjects. High throughput gene expression analysis was performed on samples from six ON patients and nine healthy subjects using Affymetrix technology. Data were analyzed using Partek software, and most informative genes (MIGs) were defined as genes with P < 0.01 and fold change > 2.0. Molecular pathways were analyzed by Ingenuity software. Verification of key MIGs was done on samples from five independent ON patients and five healthy subjects by quantitative (Q) RT-PCR and Western blot. Functional assay to test antigen presentation ability of sorted B cells was performed on blood samples from seven additional ON patients. Results. Significantly differentiating gene expression signatures consisting of 467, 55, and 55 MIGs respective of CD19+, CD14+, and CD4+ cells, were identified between ON and healthy subjects. No MIGs were detected for CD8+ cells. The major involvement of CD19+ B cells in the early stage of ON was characterized by enrichment of genes involved in activation of immune mechanisms (P = 3.2 × 10−25 to 2.5 × 10−3), including cellular immune response (P = 7.1 × 10−12), B-cell cellular growth and proliferation (P = 1.0 × 10−7), activation of immune cells trafficking pathways (P = 5.4 × 10−15 to 2.0 × 10−3), and stimulation of antigen presentation (P = 8.9 × 10−11). This massive B-cell–restricted initiation of the immune response in the early disease process of ON was followed by low CD14+ and CD4+ cells activity and CD8+ cells anergy. Conclusions. Our findings demonstrate that CD19+ B cells have a significant role in the pathogenesis of the first demyelinating event of acute ON and suggest their role as a possible target for immunomodulation.
- 15 January 2015
- Published by Association for Research in Vision and Ophthalmology (ARVO) in Investigative Ophthalmology & Visual Science
- Vol. 56 (2) , 1349-1356
The Role of B Cells in the Early Onset of the First Demyelinating Event of Acute Optic Neuritis
Purpose. We evaluated the molecular pathways that operate in the early phase of acute optic neuritis (ON) by studying gene expression profiles of peripheral blood mononuclear cells (PBMCs) subpopulations, including CD19+ B cells, CD14+ macrophages, and CD4+ and CD8+ T cells. Methods. Samples of PBMC subpopulations were obtained from 18 MS patients within 96 hours of the acute onset of the first demyelinating event of ON, and from 14 age- and sex-matched healthy subjects. High throughput gene expression analysis was performed on samples from six ON patients and nine healthy subjects using Affymetrix technology. Data were analyzed using Partek software, and most informative genes (MIGs) were defined as genes with P < 0.01 and fold change > 2.0. Molecular pathways were analyzed by Ingenuity software. Verification of key MIGs was done on samples from five independent ON patients and five healthy subjects by quantitative (Q) RT-PCR and Western blot. Functional assay to test antigen presentation ability of sorted B cells was performed on blood samples from seven additional ON patients. Results. Significantly differentiating gene expression signatures consisting of 467, 55, and 55 MIGs respective of CD19+, CD14+, and CD4+ cells, were identified between ON and healthy subjects. No MIGs were detected for CD8+ cells. The major involvement of CD19+ B cells in the early stage of ON was characterized by enrichment of genes involved in activation of immune mechanisms (P = 3.2 × 10−25 to 2.5 × 10−3), including cellular immune response (P = 7.1 × 10−12), B-cell cellular growth and proliferation (P = 1.0 × 10−7), activation of immune cells trafficking pathways (P = 5.4 × 10−15 to 2.0 × 10−3), and stimulation of antigen presentation (P = 8.9 × 10−11). This massive B-cell–restricted initiation of the immune response in the early disease process of ON was followed by low CD14+ and CD4+ cells activity and CD8+ cells anergy. Conclusions. Our findings demonstrate that CD19+ B cells have a significant role in the pathogenesis of the first demyelinating event of acute ON and suggest their role as a possible target for immunomodulation.
- 22 April 2012
- Published by Wolters Kluwer Health in Neurology
- Vol. 78 (Meeting Ab) , SC01.003
Suppression of RNA-Polymerase 1 Pathway Is Associated with Benign Multiple Sclerosis (SC01.003)
- 22 April 2012
- Published by Wolters Kluwer Health in Neurology
- Vol. 78 (Meeting Ab) , SC01.003
Suppression of RNA-Polymerase 1 Pathway Is Associated with Benign Multiple Sclerosis (SC01.003)
- 22 April 2012
- Published by Wolters Kluwer Health in Neurology
- Vol. 78 (Meeting Ab) , S40.002
Macrophage Recruitment in Secondary Progressive Multiple Sclerosis (S40.002)
- 22 April 2012
- Published by Wolters Kluwer Health in Neurology
- Vol. 78 (Meeting Ab) , S40.002
Macrophage Recruitment in Secondary Progressive Multiple Sclerosis (S40.002)
- 22 April 2012
- Published by Wolters Kluwer Health in Neurology
- Vol. 78 (Meeting Ab) , P02.138
Epidemiology of Anti-JCV Antibodies in Israeli Multiple Sclerosis Population (P02.138)
- 22 April 2012
- Published by Wolters Kluwer Health in Neurology
- Vol. 78 (Meeting Ab) , P02.138
Epidemiology of Anti-JCV Antibodies in Israeli Multiple Sclerosis Population (P02.138)
- 22 April 2012
- Published by Wolters Kluwer Health in Neurology
- Vol. 78 (Meeting Ab) , P04.111
Modeling Long-Term Cognitive Decline in Multiple Sclerosis: A Population-Based Cross-Sectional Epidemiological Study (P04.111)
- 22 April 2012
- Published by Wolters Kluwer Health in Neurology
- Vol. 78 (Meeting Ab) , P04.111
Modeling Long-Term Cognitive Decline in Multiple Sclerosis: A Population-Based Cross-Sectional Epidemiological Study (P04.111)
- 22 April 2012
- Published by Wolters Kluwer Health in Neurology
- Vol. 78 (Meeting Ab) , S20.005
Suppression of RNA-Polymerase 1 Pathway Is Associated with Benign Multiple Sclerosis (S20.005)
- 22 April 2012
- Published by Wolters Kluwer Health in Neurology
- Vol. 78 (Meeting Ab) , S20.005
Suppression of RNA-Polymerase 1 Pathway Is Associated with Benign Multiple Sclerosis (S20.005)
- 22 April 2012
- Published by Wolters Kluwer Health in Neurology
- Vol. 78 (Meeting Ab) , P02.011
Expression of CD20 by Adult Neural Progenitor Cells (P02.011)
- 22 April 2012
- Published by Wolters Kluwer Health in Neurology
- Vol. 78 (Meeting Ab) , P02.011
Expression of CD20 by Adult Neural Progenitor Cells (P02.011)
- 13 July 2011
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 311 (1-2) , 9-14
Characterization of the multiple sclerosis traits: Nuclear receptors (NR) impaired apoptosis pathway and the role of 1-alpha 25-dihydroxyvitamin D3
- 13 July 2011
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 311 (1-2) , 9-14
Characterization of the multiple sclerosis traits: Nuclear receptors (NR) impaired apoptosis pathway and the role of 1-alpha 25-dihydroxyvitamin D3